|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q3 FY2019
As of Sep 30, 2019
|
Q2 FY2019
As of Jun 30, 2019
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Federal funds sold and other short-term investments | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Debt securities available for sale, at fair value | ||||||||||||||||||||
| Debt securities held to maturity (fair value 2021 - $140,412 and 2020 - $83,246) | ||||||||||||||||||||
| Debt securities held to maturity (fair value 2024 - $291,651 and 2023 - $322,098) | ||||||||||||||||||||
| Federal Home Loan Bank (FHLB) stock | ||||||||||||||||||||
| Loans held for sale, at fair value | ||||||||||||||||||||
| Total loans | ||||||||||||||||||||
| Allowance for credit losses | ||||||||||||||||||||
| Net loans | ||||||||||||||||||||
| Premises and equipment – net | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Bank-owned life insurance | ||||||||||||||||||||
| Other real estate owned - net | ||||||||||||||||||||
| Deferred tax asset - net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||||||||||||
| Noninterest-bearing | ||||||||||||||||||||
| Interest-bearing | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Other borrowed funds | ||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||
| Accrued expenses and other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders' equity | ||||||||||||||||||||
| Common stock, no par value, 200,000,000 shares authorized; 34,361,562 issued and outstanding, respectively | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total shareholders' equity | ||||||||||||||||||||
| Total liabilities and shareholders' equity |
Loading...
